MedTrace Logo

The Heart Failure Readmission Intervention by Variable Early Follow-up (THRIVE) Study

NCT03524534 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2091

Last updated 2023-06-12

No results posted yet for this study

Summary

This study is a pragmatic randomized clinical trial to determine the effectiveness of two strategies of early follow-up in adults after hospitalization for heart failure: telephone follow-up with a heart failure care manager vs. in-person clinic visit with their primary care provider. The primary outcomes during 30-day follow-up will include readmission for heart failure, death and readmission for any cause. The study team aims to randomly assign 2400 patients during a 15-month period in a 1-to-1 ratio to either an initial structured telephone call with a heart failure care manager or an in-person primary care clinic visit within 7 days of discharge. A secondary goal is to increase the rate of any follow-up within 7 days of discharge to greater than 90 percent among all eligible patients.

Conditions

Interventions

OTHER

Telephone Call

A phone call will take place within 7 days of discharge by a Kaiser Permanente Heart Failure Care Manager from the Kaiser Permanente Heart Failure Chronic Care Management Program.

OTHER

In-Person Primary Care Clinical Follow-Up Visit

This will be a standard in-person clinic visit with the subject's primary care physician within 7 days of discharge, with no structured heart failure protocol.

Sponsors & Collaborators

  • The Permanente Medical Group

    collaborator UNKNOWN

  • Kaiser Permanente

    lead OTHER

Principal Investigators

  • Alan S. Go, MD · Kaiser Permanente

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2018-09-30
Completion
2018-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03524534 on ClinicalTrials.gov